Incannex Healthcare Inc.

Incannex Healthcare Inc. announced that Alliance Global Partners (AGP) has initiated equity research coverage of the company. AGP assigned a "BUY" rating and a price target of US$18.00 per share. Incannex believes this coverage will expand awareness of its clinical programs, including IHL-42X for obstructive sleep apnoea and PSX-001 for generalized anxiety disorder, and its investment proposition among investors.

Incannex Healthcare Inc. announced that Alliance Global Partners (AGP) has initiated equity research coverage of the company. The research report, authored by AGP Managing Director and Senior Biotechnology Analyst James Molloy, provides an independent assessment of Incannex's clinical pipeline, development strategy, market opportunities, and future growth prospects. AGP assigned a "BUY" rating with a price target of US$18.00 per share, which Incannex believes will expand investor awareness of its clinical programs, including IHL-42X and PSX-001.

Incannex Healthcare Inc. reported a net loss of $16.8 million for the nine months ended March 31, 2026, an increase from $15.3 million in the prior year. Despite increased operating losses, the company's cash and cash equivalents significantly rose to $74.5 million, primarily due to $78.6 million in proceeds from share issuances. The company also completed a 1-for-30 reverse stock split in February 2026 and anticipates funding operations for at least twelve months.

Incannex Healthcare Inc. announced the official commencement of its DReAMzz clinical study for IHL-42X, targeting obstructive sleep apnea (OSA). This study is designed for dose optimization to refine the drug's profile and strengthen the planned Phase III development program, building on positive Phase II results. The company has completed site identification, manufacturing, and secured permits, positioning IHL-42X, which holds FDA Fast Track designation, as a leading oral pharmacotherapy for OSA.

Incannex Healthcare Inc. announced the official commencement of its DReAMzz clinical study evaluating IHL-42X for the treatment of obstructive sleep apnea (OSA). This marks a significant operational and strategic milestone, with all 14 clinical trial sites identified, drug product manufacturing completed, and necessary permits secured. The DReAMzz study is designed to optimize IHL-42X's dosing profile and strengthen the design of the planned Phase III development program, building on positive Phase II data and FDA Fast Track designation.

Incannex Healthcare Inc. announced it won the "Best New Technology Solution for Drug Development" award at the 10th annual MedTech Breakthrough Awards. This recognition highlights the company's lead drug candidate, IHL-42X, an oral fixed-dose combination therapy for obstructive sleep apnea (OSA). The award validates the strong clinical progress of IHL-42X, which demonstrated statistically significant and clinically meaningful reductions in AHI, alongside improvements in oxygenation, sleep quality, and patient-reported fatigue in its Phase 2 RePOSA clinical trial.

Incannex Healthcare Inc. announced that its PSX-001 oral synthetic psilocybin program aligns with a recent White House Executive Order. The order, signed by President Donald J. Trump on April 18, 2026, aims to accelerate access to psychedelic treatments for serious mental illness. This development is expected to significantly improve the regulatory environment for Incannex's program, potentially expediting its advancement.